Granahan Investment Management, LLC Revance Therapeutics, Inc. Transaction History

Granahan Investment Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $761,986 - $1.67 Million	66,433 Added 22.99%	355,360 $4.08 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $1.12 Million - $1.71 Million	45,465 Added 18.67%	288,927 $7.31 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $1.92 Million - $3.69 Million	-104,602 Reduced 30.05%	243,462 $7.84 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $1.89 Million - $3.16 Million	103,147 Added 42.12%	348,064 $6.43 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $305,028 - $606,012	21,286 Added 9.52%	244,917 $6.61 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $713,502 - $1.26 Million	61,936 Added 38.3%	223,631 $3.09 Million
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $677,352 - $1.11 Million	-54,802 Reduced 25.31%	161,695 $3.15 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $1.1 Million - $2.46 Million	88,258 Added 68.82%	216,497 $3.53 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $3.31 Million - $4.26 Million	128,239 New	128,239 $3.57 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Granahan Investment Management, LLC with notifications on news.